APTOのチャート
APTOの企業情報
| symbol | APTO |
|---|---|
| 会社名 | Aptose Biosciences Inc （アポト―ス・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アプトス・バイオサイエンセス（Aptose Biosciences Inc）（旧名：Lorus Therapeutics Inc.）は、生命科学会社。同社は、安全性プロファイルのある効果的抗癌治療法の発見・研究・開発を行う。また、前臨床から完成第I相臨床試験に至るまで様々な段階の製品で、多様的抗がん製品パイプラインを確立する。 アポト―ス・バイオサイエンシズはカナダのバイオ医薬品企業。主に腫瘍への対応標的治療薬の発見と開発に従事する。同社はさまざまな臨床段階の医薬品と市場性のある抗がん医薬品を手掛け、主要パイプライン「LOR-253」は、急性骨髄性白血病と骨髄異形成症候群を含む高度な血液悪性腫瘍向けのものである。本社はオンタリオ州。 Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-classmutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). |
| 本社所在地 | 251 Consumers Road Suite 1105 Toronto Ontario M2J 4R3 CAN |
| 代表者氏名 | William Glenn Rice ウィリアム・グレン・ライス |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 647-479-9828 |
| 設立年月日 | 31656 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 20人 |
| url | www.aptose.com |
| nasdaq_url | https://www.nasdaq.com/symbol/apto |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -23.14960 |
| 終値（lastsale） | 2.1 |
| 時価総額（marketcap） | 72781121.7 |
| 時価総額 | 時価総額（百万ドル） 68.17641 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 49.71241 |
| 当期純利益 | 当期純利益（百万ドル） -23.04202 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aptose Biosciences Inc revenues was not reported. Net loss increased from $5.7M to $17.1M. Higher net loss reflects Research and development - Balancing val increase from $0K to $5M (expense) Program cost increase from $1.9M to $4.5M (expense) Stock-based compensation increase from $386K to $2.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.30 to -$0.54. |
APTOのテクニカル分析
APTOのニュース
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference 2023/03/02 12:30:00 GlobeNewswire
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33 rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.
Morning Worth Watching Stock: Mawson Infrastructure Group, Inc. (NASDAQ:MIGI 4.47%), Aptose Biosciences Inc. (NASDAQ:APTO -0.83%) 2023/02/06 17:43:58 Stock Equity
MIGI has seen its SMA50 which is now 65.60%. In looking the SMA 200 we see that the stock has seen a -43.82%. APTO has seen its SMA50 which is … The post Morning Worth Watching Stock: Mawson Infrastructure Group, Inc. (NASDAQ:MIGI 4.47%), Aptose Biosciences Inc. (NASDAQ:APTO -0.83%) appeared first on Stocks Equity .
How should investors view Aptose Biosciences Inc. (APTO)? 2023/01/31 13:08:00 US Post News
In Monday’s session, Aptose Biosciences Inc. (NASDAQ:APTO) marked $0.74 per share, down from $0.76 in the previous session. While Aptose Biosciences Inc. has underperformed by -2.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APTO fell by -34.43%, with highs and lows ranging from $1.55 to […]
Eye-popping stocks: Aptose Biosciences Inc. (NASDAQ:APTO -3.68%), TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ 1.96%) 2023/01/30 16:59:50 Stock Equity
APTO has seen its SMA50 which is now 14.95%. In looking the SMA 200 we see that the stock has seen a -5.36%. RNAZ has seen its SMA50 which is … The post Eye-popping stocks: Aptose Biosciences Inc. (NASDAQ:APTO -3.68%), TransCode Therapeutics, Inc. Common Stock (NASDAQ:RNAZ 1.96%) appeared first on Stocks Equity .
Aptose Biosciences Inc. (NASDAQ: APTO): Can A Stock That’s Down -57.04% YTD Still Be Considered In Loss Territory? 2022/12/31 14:30:00 Marketing Sentinel
During the last session, Aptose Biosciences Inc. (NASDAQ:APTO)’s traded shares were 0.38 million, with the beta value of the company hitting 1.54. At the end of the trading day, the stock’s price was $0.58, reflecting an intraday gain of 7.61% or $0.04. The 52-week high for the APTO share is $1.55, that puts it down … Aptose Biosciences Inc. (NASDAQ: APTO): Can A Stock That’s Down -57.04% YTD Still Be Considered In Loss Territory? Read More »
Aptose Biosciences (APTO) Investor Presentation - Slideshow (NASDAQ:APTO) 2022/09/14 13:46:19 Seeking Alpha
The following slide deck was published by Aptose Biosciences Inc.
Oppenheimer Equities Analysts Raise Earnings Estimates for Aptose Biosciences Inc. (NASDAQ:APTO) 2022/08/05 08:01:32 ForexTV
During the same quarter in the previous year, the business earned ($0.18) earnings per share. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald decreased … Read Full Story at source (may require registration) The post Oppenheimer Equities Analysts Raise Earnings Estimates for Aptose Biosciences Inc. (NASDAQ:APTO) appeared first on ForexTV .
FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation 2022/05/04 12:41:58 Benzinga
Aptose Biosciences Inc. (NASDAQ: APTO ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. HM43239 is being investigated in an ongoing international Phase 1/2 … Full story available on Benzinga.com
Aptose Biosciences Q4 2021 Earnings Preview (NASDAQ:APTO) 2022/03/21 21:35:43 Seeking Alpha
Aptose Biosciences (APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close.The consensus EPS Estimate is -$0.17Over the last 3 months, EPS…
Aptose to Present at Oppenheimer''s 32nd Annual Healthcare Conference 2022/03/01 12:30:00 Benzinga
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com
FDA Grants Fast Track designation To Aptose Biosciences for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation 2022/05/04 12:41:58 Benzinga
Aptose Biosciences Inc. (NASDAQ: APTO ) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. HM43239 is being investigated in an ongoing international Phase 1/2 … Full story available on Benzinga.com
Aptose Biosciences Q4 2021 Earnings Preview (NASDAQ:APTO) 2022/03/21 21:35:43 Seeking Alpha
Aptose Biosciences (APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close.The consensus EPS Estimate is -$0.17Over the last 3 months, EPS…
Aptose to Present at Oppenheimer''s 32nd Annual Healthcare Conference 2022/03/01 12:30:00 Benzinga
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO , TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer''s 32 nd Annual Healthcare Conference: Aptose Presentation - Oppenheimer''s 32nd Annual Healthcare Conference Date: Tuesday, March 15, 2022 Time: 10:00 … Full story available on Benzinga.com
Aptose Biosciences Inc Shares Close the Day 12.6% Higher - Daily Wrap 2022/01/04 10:48:15 Kwhen Finance
Aptose Biosciences Inc (APTO) shares closed today 12.6% higher than it did at the end of yesterday. The stock is currently up 12.6% year-to-date, down 65.3% over the past 12 months, and up 12.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.55 and as low as $1.30 this week.Shares closed 78.9% below its 52-week high and 40.7% above its 52-week low.Trading volume this week was 3.6% higher than the 10-day average and 56.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 115.4% The company's stock price performance over the past 12 months lags the peer average by -4010.3%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.